Cited by TERT Gene Mutation in Gliomas Cross‐Linked With (NTRK, PDL1, ALK, IDH, P53, EGFR, HER2): A Integrative Review TERT Gene Mutation in Gliomas

Identification of ferroptosis-related LncRNAs as potential targets for improving immunotherapy in glioblastoma DOI

Zhaochen Wang, Xiao Jin,

Xiaoli Yong

et al.

Computer Methods in Biomechanics & Biomedical Engineering, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 13

Published: Jan. 1, 2025

The effect of ferroptosis-related long non-coding RNAs (lncRNAs) in predicting immunotherapy response to glioblastoma (GBM) remains obscure. This study established a 11-lncRNAs prognostic signature. Differential gene expression analysis, univariate and multivariate Cox regression analyses the least absolute shrinkage selection operator (LASSO) algorithm were used identify genes establish nomogram model risk score. Kaplan-Meier survival plots receiver operating characteristic (ROC) curve analysis evaluate accuracy TCGA-GBM cohort. To verify these signatures, we analyzed levels three lncRNAs (AGAP2-AS1, OSMR-AS1, UNC5B-AS1) LN229 U87 cells. ROC showed that area under (AUC) this signature is 0.814, suggesting it has promising performance on GBM prediction. rate patients high-risk group was significantly lower than low-risk group, prediction superior conventional clinicopathological factors. Further qRT-PCR experiment also confirmed our lncRNA signatures. These might be therapeutic targets for glioblastoma, targeting can improve efficacy immunotherapy, especially immune checkpoint inhibitors. Mechanistically, findings attribute N6-methyladenosine (m6A) mRNA modification lncRNAs.

Language: Английский

Citations

PD-1 mediates microglia polarization via the MAPK signaling pathway to protect blood-brain barrier function during cerebral ischemia/reperfusion DOI

Linqiang Huang,

Xinping Li, Zhuo Li

et al.

Brain Research Bulletin, Journal Year: 2024, Volume and Issue: 216, P. 111055 - 111055

Published: Aug. 22, 2024

Cerebral ischemia is characterized by its rapid onset and high rates of recurrence, morbidity, mortality, with blood-brain barrier (BBB) permeability playing a vital role in brain injury. Therefore, it important to understand the molecular mechanism which regulates BBB during cerebral ischemia.

Language: Английский

Citations

Clinical immunotherapy in glioma: current concepts, challenges, and future perspectives DOI

Jun Liu, Jianan Peng, Jian Jiang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 1, 2024

Glioma is one of the common tumors in central nervous system, and its treatment methods (surgery, radiotherapy, chemotherapy) lack specificity have a poor prognosis. With development immunology, cell biology, genomics, tumor immunotherapy has ushered new era therapy, achieving significant results other invasive cancers such as advanced melanoma non-small lung cancer. Currently, clinical trials glioma are also progressing rapidly. Here, this review summarizes promising recent years, reviews current status trials, discusses challenges prospects immunotherapy.

Language: Английский

Citations

TERT Gene Mutation in Gliomas Cross‐Linked With (NTRK, PDL1, ALK, IDH, P53, EGFR, HER2): A Integrative Review TERT Gene Mutation in Gliomas DOI

Guilherme Augusto dos Santos, Guilherme Nobre Nogueira, Iasmin Maria Rodrigues Saldanha

et al.

Journal of Surgical Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 7, 2024

Recent advancements in glioma treatment are largely driven by the identification of genetic alterations, which enhance diagnostic precision and prognostic assessments, unveil potential therapeutic targets. TERT promoter mutations, particular, associated with a poorer prognosis aggressive clinical behavior.

Language: Английский

Citations